Understanding Healthcare Professionals’ Concerns
In the ever-evolving healthcare landscape, the role of General Practitioners (GPs) is pivotal. They are often the first point of contact for patients and are responsible for diagnosing a wide range of medical conditions. However, when it comes to rare medical diseases, GPs face significant challenges.
The infrequency and complexity of these conditions can lead to delayed diagnoses, misdiagnoses, and suboptimal patient care.
With over 7,000 rare diseases identified worldwide[1], it is nearly impossible for GPs to be familiar with all of them. As one GP explained, “Rare things are rare,[2]” highlighting the inherent difficulty in encountering these conditions regularly.
In a recent AusDoc study into GP awareness and management of rare diseases, when asked “How confident are you in recognising symptoms that could indicate a rare disease?”, only 14.7% said that they were ‘Fairly Confident’ or ‘Completely Confident”.
“Symptoms of rare disease can masquerade as more common conditions with no reliable features to differentiate them on clinical grounds.”
“Difficult to keep across everything in medicine if not challenged regularly to diagnose it”
The respondents ranked limited knowledge of specific diseases (74%) as their biggest challenge. This was followed by:
| Lack of readily available guides on differential diagnoses | (47.4%) |
| Time constraints in practice | (47.4%) |
| Lack of access to diagnostic tools | (46.6%) |
| Difficulty in accessing specialist support | (40.0%) |
While it’s unrealistic for busy GPs to be on top of every rare disease, these survey results point to an opportunity to raise awareness among doctors.
“Timely and accurate diagnosis is critical to enabling access to best practice clinical care and treatments, some of which can be life changing or lifesaving,” says a factsheet published by peak body Rare Voices Australia.
For pharmaceutical companies, investing in the education of GPs about rare diseases is not just a matter of corporate social responsibility but also a strategic imperative that can yield substantial benefits.
1. Enhancing Early Diagnosis and Treatment
One of the most critical reasons for pharma companies to invest in educating GPs about rare diseases is the potential for early diagnosis and intervention. Early diagnosis is crucial for the management of rare diseases, as it can significantly improve the prognosis and quality of life for patients.
“Thirty per cent of Australian adults living with a rare disease are impacted by a diagnostic delay of more than five years, and almost half of these have received at least one misdiagnosis,” according to Rare Diseases.
GPs are already looking for additional support to help them identify rare diseases more effectively:
“What additional support would help you identify rare diseases more effectively? Select ALL that apply.”
| Improved diagnostic tools | 61.9% |
| Comprehensive clinical decision support systems | 59.5% |
| Access to specialist networks | 58.7% |
| Regular training and workshops | 47.6% |
As the prevalence of rare diseases continues to grow, it is clear that more support and resources will be necessary to help GPs confidently manage these cases.
By providing GPs with the necessary knowledge and tools to recognise these symptoms, pharma companies can help ensure that patients receive timely and accurate diagnoses.
2. Building Stronger Relationships with Healthcare Providers
Educational initiatives targeted at GPs can help pharma companies build stronger, more collaborative relationships with healthcare providers. By offering valuable resources and training, pharma companies position themselves as trusted partners in the healthcare ecosystem.
Continuing education in rare disease is already a concern with over 31% of GPs having not participated in training or any continuing education related to rare diseases in the last year and 29% answering “never”.
This collaboration can lead to better-informed treatment decisions, increased trust in pharmaceutical products, and a more positive perception of the company within the medical community.
The most preferred learning methods identified in the AusDoc study were online CPD-accredited education (65.9%) and educational webinars (56.4%). These digital formats provide flexibility and accessibility for busy GPs.
3. Supporting the Development and Adoption of Orphan Drugs
The development of orphan drugs, which are medications specifically designed to treat rare diseases, is a growing focus for many pharma companies. However, the success of these drugs depends largely on the awareness and knowledge of GPs who are responsible for prescribing them.
By investing in the education of GPs, pharma companies can facilitate the adoption of orphan drugs, ensuring that patients who need these treatments have access to them. This not only helps to recoup the substantial investment involved in developing these drugs but also drives innovation and advancement in the field of rare disease treatment.
4. Addressing Unmet Medical Needs
Patients with rare diseases often face significant challenges in accessing appropriate care and treatment. These conditions are frequently underdiagnosed and undertreated, leading to considerable unmet medical needs.
By equipping GPs with the knowledge to identify and manage rare diseases, pharma companies can help bridge this gap. This effort aligns with the broader mission of improving patient outcomes and advancing medical knowledge. Additionally, addressing unmet medical needs can open up new markets and opportunities for pharma companies, driving growth and innovation.
5. Enhancing Public Health Outcomes
The education of GPs about rare diseases has far-reaching implications for public health. When GPs are better informed about these conditions, they can provide more comprehensive care, reducing the burden on specialist services and improving overall health outcomes.
Furthermore, increased awareness among GPs can lead to more accurate epidemiological data, helping to inform public health policies and resource allocation. This, in turn, can lead to better prevention, management, and treatment strategies for rare diseases at a population level.
Conclusion
Investing in the education of GPs about rare medical diseases is a strategic move that offers numerous benefits for pharma companies. It enhances early diagnosis and treatment, builds stronger relationships with healthcare providers, supports the development and adoption of orphan drugs, addresses unmet medical needs, and improves public health outcomes.
As the landscape of healthcare continues to evolve, pharma companies that prioritise the education of GPs will not only contribute to better patient care but also position themselves as leaders in the field of rare disease treatment. This investment is a testament to the industry’s commitment to advancing medical knowledge and improving the lives of patients with rare diseases.
Contact us
Looking to run a campaign and engage doctors with confidence? For further information, contact us to discuss how AusDoc can support you with the reassurance you need.
Source
[1] National Institutes of Health (NIH), Office of Rare Diseases Research.
[2] https://rarevoices.org.au/
AusDoc: Survey for General Practitioners on the Awareness and Management of Rare Diseases Sept 2024 (n=159)
This article was written with the assistance of AI